SUMMARY
# Validation: Membrane-Nucleation in iPSC Neurons
## Background and Rationale
The validation study of membrane-nucleation mechanisms in iPSC-derived neurons represents a crucial translational bridge between fundamental biochemical discoveries and clinically relevant cellular models in Parkinson's disease research. This investigation builds upon compelling evidence that membrane lipid composition, particularly the presence of anionic phospholipids such as phosphatidylserine and phosphatidylinosit
METHODOLOGY NOTES
**Phase 1: iPSC-Derived Neuron Preparation (Weeks 1-6)**
• Differentiate human iPSCs (n=6 cell lines, 3 healthy controls + 3 PD patients with SNCA mutations) into dopaminergic neurons using dual SMAD inhibition protocol
• Validate neuronal identity at day 35-42 using immunofluorescence (TH+, MAP2+, β-tubulin III+)
• Confirm dopaminergic phenotype with HPLC analysis of dopamine production
• Seed neurons at 50,000 cells/well in 96-well imaging plates for membrane composition analysis
**Phase 2: Membrane Lipid Composition Manipulation (Week 7)**
• Treat neurons with lipid supplementation medium containing: PS (25-100 μM), PIP2 (10-50 μM), or vehicle control
• Include positive control with rotenone (100 nM) and negative control with cholesterol supplementation
• Incubate for 48-72 hours with daily medium changes
• Validate membrane incorporation using mass spectrometry lipidomics (LC-MS/MS)
**Phase 3: Alpha-Synuclein Analysis (Week 8)**
• Fix cells at 24h, 48h, and 72h timepoints for imm